SCHEMBL689464

SCHEMBL689464

CN(C)S(=O)(=O)c1ccc2c(c1)CC(=O)N2

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GAA P10253 7/20 0.56
PKM P14618 3/20 0.53
HTR2C P28335 1/20 0.51
HTR2B P41595 1/20 0.51
ALDH1A1 P00352 2/20 0.50
SMYD3 Q9H7B4 1/20 0.50
MAPT P10636 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2C19 P33261 1/20 0.50
IDO1 P14902 1/20 0.50
AHR P35869 1/20 0.50
PDE3B Q13370 1/20 0.49
PDE3A Q14432 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12431410 0.87 GAA (0.52) GAAPKMALDH1A1SMYD3MAPT
SCHEMBL7672998 0.83 GAA (0.53) GAAPKMALDH1A1SMYD3MAPT
SCHEMBL3658452 0.83 ALDH1A1 (0.53) GAAPKMALDH1A1SMYD3MAPT
SCHEMBL3248876 0.83 ALDH1A1 (0.62) GAAPKMHTR2CHTR2BALDH1A1
SCHEMBL1556955 0.82 GAA (0.60) GAAPKMSMYD3MAPTTDP1
SCHEMBL4608466 0.81 PKM (0.57) PKMALDH1A1MAPTCYP1A2CYP3A4
SCHEMBL12431405 0.81 GAA (0.53) GAAPKMHTR2CALDH1A1SMYD3
SCHEMBL7496956 0.81 ALDH1A1 (0.51) GAAPKMALDH1A1MAPTTDP1
SCHEMBL6602558 0.79 GAA (0.57) GAAPKMSMYD3MAPTTDP1
SCHEMBL2203244 0.79 GAA (0.64) GAAPKMSMYD3MAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147586-A1 Indolinone derivatives as protein kinase/phosphatase inhibitors SUGEN, INC. 2004-07-29 US claimed
EP-1294688-A2 INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS Sugen, Inc. (US) 2003-03-26 EP claimed
JP-2002540096-A 2002-11-26 JP claimed
US-20020052369-A1 Indolinone derivatives as protein kinase/phosphatase inhibitors SUGEN, INC. 2002-05-02 US claimed
EP-1165513-A1 INDOLINONE COMPOUNDS AS KINASE INHIBITORS Sugen, Inc. (US) 2002-01-02 EP claimed
WO-2001094312-A2 INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS SUGEN, INC. (US) 2001-12-13 WO claimed
WO-2000056709-A1 INDOLINONE COMPOUNDS AS KINASE INHIBITORS SUGEN, INC. (US) 2000-09-28 WO claimed
US-20170057948-A1 INDOLE-LIKE TRK RECEPTOR ANTAGONISTS UNIVERSITY OF TARTU (EE) 2017-03-02 US disclosed
EP-1918277-B1 Azulene compounds IND TECH RES INST (TW) 2015-06-10 EP disclosed
EP-1918277-B1 Azulene compounds IND TECH RES INST (TW) 2015-06-10 EP disclosed
CN-101448822-B Substituted pyrazolopyrimidines CEPHALON INC 2013-11-06 CN disclosed
US-8354414-B2 Substituted bicyclic pyrimidines CEPHALON, INC (US) 2013-01-15 US disclosed
EP-2123649-B1 3-PYRROLO-CYCLOHEXYLENE-2-DIHYDRO-INDOLINONE DERIVATIVES AND USES THEREOF JIANGSU SIMCERE PHARMACEUTICAL R & D CO LTD (CN) 2012-02-29 EP disclosed
EP-0984930-A1 2-INDOLINONE DERIVATIVES AS MODULATORS OF PROTEIN KINASE ACTIVITY Sugen, Inc. (US) 2000-03-15 EP disclosed
WO-2000008202-A2 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE SUGEN, INC. (US) 2000-02-17 WO disclosed
WO-1999061422-A1 PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS SUGEN, INC. (US) 1999-12-02 WO disclosed
WO-1999048868-A2 HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE SUGEN, INC. (US) 1999-09-30 WO disclosed
EP-0912557-A1 OXINDOLE DERIVATIVES ZENECA LIMITED (GB) 1999-05-06 EP disclosed
WO-1998050356-A1 2-INDOLINONE DERIVATIVES AS MODULATORS OF PROTEIN KINASE ACTIVITY SUGEN, INC. (US) 1998-11-12 WO disclosed
WO-1997042187-A1 OXINDOLE DERIVATIVES ZENECA LIMITED (GB) 1997-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170057948-A1 INDOLE-LIKE TRK RECEPTOR ANTAGONISTS NTRK3, NTRK1, MUSK GAA 4848/4885PKM 2190/4885HTR2C 284/4885
US-20040147586-A1 Indolinone derivatives as protein kinase/phosphatase inhibitors PHKA1, PHKA2, PDPK1 GAA 714/4885PKM 246/4885HTR2C 1156/4885
US-20020052369-A1 Indolinone derivatives as protein kinase/phosphatase inhibitors PHKA1, PHKA2, PDPK1 GAA 714/4885PKM 246/4885HTR2C 1156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.